Deucrictibant - Pharvaris
Alternative Names: PHA-022121; PHA-121; PHVS 416; PHVS 719; PHVS416 - soft capsule formulation; PHVS719 - XR tabletLatest Information Update: 13 Mar 2025
At a glance
- Originator Pharvaris
- Class Acetamides; Benzene derivatives; Ethers; Halogenated hydrocarbons; Organic deuterium compounds; Quinolines; Skin disorder therapies; Small molecules; Triazoles; Vascular disorder therapies
- Mechanism of Action Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hereditary angioedema
- Clinical Phase Unknown Angioedema
Most Recent Events
- 03 Mar 2025 Efficacy and adverse evet data from the phase II HAE CHAPTER-1 trial in Hereditary angioedema released by Pharvaris
- 01 Feb 2025 Pharvaris initiates enrolment in its phase-III CHAPTER-4 clinical trial in Hereditary angioedema (In adults, In adolescents, In the elderly) in United Kingdom, Hong Kong (PO) (NCT06679881)
- 13 Jan 2025 Pharvaris plans a clinical trial in Angioedema in 2025